These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7871203)

  • 1. [Effect of furosemide added to peritoneal dialysis fluid on hydroxyproline excretion in dialysate and urine].
    Sucharzewska-Tomczak M; Grzegorzewska A
    Przegl Lek; 1994; 51(7):300-2. PubMed ID: 7871203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estimation of hearing in patients with end stage renal failure being peritoneally dialyzed with and without furosemide in the dialysis fluid].
    Korytowska A; Grzegorzewska A
    Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1087-9. PubMed ID: 1305731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levels of plasma proteins in patients with ene stage renal failure treated with peritoneal dialysis with an addition of furosemide to dialysis fluid].
    Grzegorzewska A; Krzymański M; Antoniewicz K
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):137-40. PubMed ID: 8090666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
    Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
    Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
    Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
    Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal exchange volume and dialysate flow rate in peritoneal dialysis. A clinical study.
    Kalra OP; Abrol L; Chopra JS; Agarwal SK; Prakash C
    J Assoc Physicians India; 1989 Dec; 37(12):762-4. PubMed ID: 2699986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxidase activity in peritoneal neutrophils of patients with terminal renal failure treated by intermittent peritoneal dialysis.
    Sułowicz W; Hanicki Z; Labza H; Basta A
    Med Interne; 1990; 28(2):135-8. PubMed ID: 2176739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of intraperitoneal furosemide administration on levels of +proteins+ in plasma and signs of their ability to be dialyzed during intermittent peritoneal dialysis].
    Grzegorzewska A; Krzymański M; Antoniewicz K
    Pol Tyg Lek; 1991 Jan 21-28; 46(4-5):67-70. PubMed ID: 1845696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Composition of amino acid in blood and dialysate by patients with in chronic renal insufficiency by peritoneal dialysis].
    Pichugina IS; Gapparov MM; Chukarina EV; Vetchinnikova ON; Vatazin AV
    Vopr Pitan; 2008; 77(3):45-8. PubMed ID: 18669331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vasodilator and surface active drugs on the efficacy of peritoneal dialysis.
    Kalra OP; Aggarwal HK; Mahajan SK; Seth RK
    J Assoc Physicians India; 1992 Apr; 40(4):233-6. PubMed ID: 1452528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dialysate CA125 levels in stable peritoneal dialysis patients.
    Okada T; Nakao T; Matsumoto H
    Clin Nephrol; 1999 Jan; 51(1):65-6. PubMed ID: 9988153
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis].
    Grzegorzewska A; Antoniewicz K; Kuźniak J; Zawadzka E
    Przegl Lek; 1990; 47(10):686-90. PubMed ID: 2089444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child.
    Porto I; John EG; Heilliczer J
    Pharmacotherapy; 1997; 17(4):832-5. PubMed ID: 9250568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis.
    Heimbürger O
    Kidney Int Suppl; 1996 Nov; 56():S47-55. PubMed ID: 8914054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of various pharmacologic and conventional methods of increasing the effectiveness of peritoneal dialysis. IV. A large intraperitoneal dose of furosemide in the modeling of continuous peritoneal dialysis].
    Grzegorzewska A
    Przegl Lek; 1988; 45(11):770-5. PubMed ID: 3244842
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline and time-averaged fluid removal affect technique survival in peritoneal dialysis in a non-linear fashion.
    Wiggins KJ; Rumpsfeld M; Hawley CM; O'Shea A; Isbel NM; Campbell SB; Johnson DW
    Nephrology (Carlton); 2007 Jun; 12(3):218-23. PubMed ID: 17498115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure].
    Mydlík M; Derzsiová K; Zemberová E; Rajnic A
    Vnitr Lek; 1998 Mar; 44(3):127-31. PubMed ID: 9820088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.